SCHEMBL5542286

SCHEMBL5542286

[CH2]c1cc2cccc(OC)c2s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.54
PARP15 Q460N3 1/20 0.41
PARP10 Q53GL7 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
NQO1 P15559 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
LMNA P02545 2/20 0.39
RECQL P46063 1/20 0.39
ALDH1A1 P00352 5/20 0.39
CYP3A4 P08684 2/20 0.39
NQO2 P16083 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KMT2A Q03164 1/20 0.38
CHRNA7 P36544 3/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4805151 0.82 CA2 (0.56) CA2PARP15PARP10TNKS2NQO1
SCHEMBL5534861 0.82 ALDH1A1 (0.42) CA2CA12CA1CA9LMNA
SCHEMBL5535970 0.80 CHRNA7 (0.41) CA2CYP3A4CHRNA7KDM4EHTR3A
SCHEMBL146428 0.78 CA2 (0.56) CA2PARP15PARP10TNKS2NQO1
SCHEMBL5545117 0.78 KDM4E (0.39) CA2NQO1ALDH1A1CYP3A4TDP1
SCHEMBL16023584 0.77 CA2 (0.54) CA2PARP15PARP10TNKS2NQO1
SCHEMBL4803731 0.77 CA2 (0.54) CA2PARP15PARP10TNKS2NQO1
SCHEMBL24227131 0.74 CA2 (0.51) CA2PARP15PARP10TNKS2NQO1
SCHEMBL12045229 0.74 CA2 (0.51) CA2PARP15PARP10TNKS2NQO1
SCHEMBL12024990 0.74 CA2 (0.51) CA2PARP15PARP10TNKS2NQO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CA2 1853/4885PARP15 4183/4885PARP10 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.